文献速递区域麻醉与超声疼痛医学

罗哌卡因?不,原文是利多卡因-布比卡因混合液:神经周围地塞米松与地塞米松-右美托咪定联合用于锁骨下臂丛阻滞的随机比较

Randomized comparison between perineural dexamethasone and combined perineural dexamethasone-dexmedetomidine for ultrasound-guided infraclavicular block.
PubMed 文献 · Reg Anesth Pain Med · 2022-06-21

这项随机试验比较超声引导锁骨下臂丛阻滞中神经周围地塞米松单用与地塞米松-右美托咪定联用,50例上肢手术患者随机分组。结果显示两组成功率、起效时间和手术麻醉无差异,但联用组运动阻滞、感觉阻滞和术后镇痛持续时间更长。

要点

  • 联用组感觉阻滞和术后镇痛持续时间也显著延长。
  • 两组阻滞成功率、起效时间和手术麻醉发生率无差异。

核心结论

  • 与神经周围地塞米松2 mg单用相比,联合右美托咪定50 μg可延长感觉运动阻滞和镇痛持续时间。

研究设计与样本

  • 随机对照试验,50例超声引导锁骨下臂丛阻滞下行上肢手术的患者,随机接受地塞米松2 mg或地塞米松2 mg-右美托咪定50 μg神经周围注射。

主要发现

  • 联用组运动阻滞持续时间21.5(2.7)小时 vs 单用组17.0(3.9)小时,p<0.001,95%CI 2.6至6.4。
  • 联用组感觉阻滞持续时间21.6(3.6)小时 vs 单用组17.2(3.6)小时,p<0.001,95%CI 2.2至6.5。
  • 联用组术后镇痛持续时间25.5(9.4)小时 vs 单用组23.5(5.6)小时,p=0.038,95%CI 1.0至7.7。
  • 两组阻滞成功率、起效时间和手术麻醉发生率无组间差异。

关键数值与推荐

  • 阻滞成功定义为30分钟时最小感觉运动复合评分达到16分中的14分。
  • 起效时间定义为达到最小复合评分14分所需时间。
  • 手术麻醉定义为无需局部浸润、补充阻滞、静脉阿片类药物或全身麻醉即可完成手术。

临床怎么用

  • 在锁骨下臂丛阻滞中,若需延长阻滞和镇痛时间,可考虑地塞米松2 mg联合右美托咪定50 μg神经周围注射。
  • 联用方案不改善阻滞成功率或起效时间,临床选择应权衡延长阻滞的获益与潜在风险。

局限性

  • 样本量仅50例,结论需更大样本验证。
  • 最佳地塞米松-右美托咪定剂量组合尚未确定,需进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This randomized trial compared perineural dexamethasone with combined perineural dexamethasone-dexmedetomidine for ultrasound-guided infraclavicular block. We hypothesized that the combination of perineural adjuvants would result in a longer motor block. METHODS: Fifty patients undergoing upper limb surgery with ultrasound-guided infraclavicular block (using 35 mL of lidocaine 1%-bupivacaine 0.25% with epinephrine 5 µg/mL) were randomly allocated to receive perineural dexamethasone (2 mg) or combined perineural dexamethasone (2 mg)-dexmedetomidine (50 µg). After the performance of the block, a blinded observer assessed the success rate (defined as a minimal sensorimotor composite score of 14 out of 16 points at 30 min), the onset time (defined as the time required to reach a minimal composite score of 14 points) as well as the incidence of surgical anesthesia (defined as the ability to complete surgery without local infiltration, supplemental blocks, intravenous opioids or general anesthesia).Postoperatively, the blinded observer contacted patients with successful blocks to inquire about the duration of motor block, sensory block and postoperative analgesia. RESULTS: No intergroup differences were observed in terms of success rate, onset time and surgical anesthesia. Compared with dexamethasone alone, combined dexamethasone-dexmedetomidine provided longer durations of motor block (21.5 (2.7) vs 17.0 (3.9) hours; p<0.001; 95% CI 2.6 to 6.4), sensory block (21.6 (3.6) vs 17.2 (3.6) hours; p<0.001; 95% CI 2.2 to 6.5), and postoperative analgesia (25.5 (9.4) vs 23.5 (5.6) hours; p=0.038; 95% CI 1.0 to 7.7). CONCLUSION: Compared with perineural dexamethasone (2 mg) alone, combined perineural dexamethasone (2 mg)-dexmedetomidine (50 µg) results in longer durations of sensorimotor block and analgesia. Further studies are required to determine the optimal dosing combination for dexamethasone-dexmedetomidine. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier: NCT04875039.

来源:Reg Anesth Pain Med,查看原文。版权归原作者所有。

引用

  1. Aliste J, Layera S, Bravo D, et al. Randomized comparison between perineural dexamethasone and combined perineural dexamethasone-dexmedetomidine for ultrasound-guided infraclavicular block. Reg Anesth Pain Med. 2022. PMID: 35728840. doi:10.1136/rapm-2022-103760

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。